Memory loss is an early feature of the disease, which progresses to loss of cognitive ability, language, social function, and ultimately death. It is the most common cause of dementia and is becoming increasingly prevalent due to increases in longevity.
It is estimated that by 2050, 1 in 49 Americans will have Alzheimer's disease. Given the epidemic like projections, Alzheimer's disease represents an important therapeutic area in drug development. There are 2 classes of drugs currently approved for the treatment of Alzheimer's disease, but neither can reverse or halt the progression of the disease. Over the last decade, several potential disease modifying drugs have been developed, but have consistently failed in clinical trials. One of our goals is to provide animal models for the development of therapeutics that will eradicate Alzheimer's disease.
We provide specialized and tailored studies in both rodents and dogs that can be used to screen potential therapeutics for symptomatic effects as well as disease modifying effects. Our translational approach across species can be used to effectively bring your therapeutic from early proof of concept to a characterized clinical candidate. With over 100 years combined of academic and industry experience within the Alzheimer's field, our team of scientists can provide you with the scientific expertise to leverage your drug development program. Our team can also provide world-class expertise in cognitive assessment, in vivo imaging and CSF sampling. The combination of these services will allow you to assess domain specific effects of therapeutics, including effects on memory, attention, and executive function, as well as biomarkers either acutely or longitudinally. We can provide you with the information you need to better understand your development product.